TELA Bio (TELA) Projected to Post Quarterly Earnings on Tuesday

TELA Bio (NASDAQ:TELA) is expected to announce its Q4 2025 results after the market closes on Tuesday, March 24th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $21.0410 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:30 PM ET.

TELA Bio Price Performance

Shares of TELA stock opened at $0.74 on Tuesday. The firm has a fifty day moving average of $0.89 and a two-hundred day moving average of $1.18. The firm has a market cap of $29.68 million, a P/E ratio of -0.83 and a beta of 0.88. TELA Bio has a 1-year low of $0.67 and a 1-year high of $2.48. The company has a debt-to-equity ratio of 26.65, a current ratio of 3.30 and a quick ratio of 2.62.

Analysts Set New Price Targets

TELA has been the subject of a number of research reports. Lake Street Capital reiterated a “buy” rating on shares of TELA Bio in a research note on Monday, December 1st. Loop Capital set a $3.00 price objective on TELA Bio in a research note on Monday, December 1st. Canaccord Genuity Group reduced their target price on TELA Bio from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its holdings in shares of TELA Bio by 101.4% during the fourth quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock valued at $152,000 after purchasing an additional 64,800 shares during the period. Susquehanna International Group LLP raised its stake in shares of TELA Bio by 551.2% during the third quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after purchasing an additional 72,594 shares in the last quarter. Citadel Advisors LLC lifted its holdings in TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after purchasing an additional 21,781 shares during the period. Finally, XTX Topco Ltd acquired a new stake in TELA Bio in the fourth quarter worth about $48,000. Institutional investors own 94.35% of the company’s stock.

About TELA Bio

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.